Clinical trial
Anrotinib Combined With Tirelizumab in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT05981157 is registered in ClinicalTrials.gov with Zhongshan People's Hospital, Guangdong, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anrotinib Combined With Tirelizumab in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
- Lead sponsor
- Zhongshan People's Hospital, Guangdong, China
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 1, 2023
- Completion date
- December 30, 2025
- Enrollment
- 27 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.